-
Mashup Score: 24Atezolizumab does not improve prognosis early relapsing adv TNBC - 13 hour(s) ago
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefi
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13New insights into the evolutionary pattern of breast cancer - 13 hour(s) ago
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 26Making personalised precision medicine reality for breast cancer - 16 hour(s) ago
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but multidisciplinary teams must adapt
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8The growing role of AI in breast cancer - 19 hour(s) ago
Rapidly increasing integration of AI into breast cancer management calls for definition of expected levels of evidence and regulatory processes
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
#ESMOBreast24: The rapidly increasing integration of #AI into many aspects of #BreastCancer management calls for an urgent definition of expected levels of evidence and bespoke regulatory & reimbursement processes. 👇Read the #ESMODailyReporter editorial https://t.co/BonyvLpHuj https://t.co/YBALLXmXSt
-
-
Mashup Score: 10ESMO Daily Reporter - 2 day(s) ago
The Daily Reporter is a service from ESMO, Europe’s leading medical oncology society
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
While novel agents continue to enrich the therapeutic armamentarium in #mCRC, patients expect not only prolonged survival, but also higher #QoL. @dice_europe #ESMOGI24 Read the interview with Eric Van Cutsem and Zorana Maravic on the #ESMODailyReporter 👉https://t.co/zEMXrndOR7 https://t.co/CS8ViwUKE1
-
-
Mashup Score: 26Prolonged adjuvant imatinib shows promise in localised GIST - 6 day(s) ago
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of careÂ
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 30Fuzuloparib prolongs PFS in HER2- metastatic breast cancer - 6 day(s) ago
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15How much ‘green’ is cancer research? - 16 day(s) ago
Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet-
What is the #EnvironmentalImpact of #ClinicalTrials? @pawel_sobczuk reflects on how novel approaches may help researchers reshape activities for greater #sustainability. #CarbonFootprint #ClimateChange Read more in #OneHealth column on #ESMODailyReporter 👉https://t.co/vZjTESAn6E https://t.co/qa3WdEFpra
-
-
Mashup Score: 10Treating colorectal cancer in the biomarker era – what's next? - 20 day(s) ago
Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
IMpassion132 trial results: Atezolizumab does not improve survival in early relapsing advanced #TNBC but shows a higher objective response rate compared to placebo. #ESMOBreast24 #ESMODailyReporter 👉https://t.co/kCaP9aNmw3 https://t.co/P6LPttaz7x